

# CorNotes

## CVI JOURNAL CLUB

September 12.....Dr. Cribbs  
September 26.....Dr. Mestril

For further information, contact Dr. Byron at x72819

## CVI SEMINAR SERIES

The next CVI seminar will be held on **Thursday, September 19, 2002 at 4:00 p.m.** in **Building 120, Rm 360** (Cuneo Center Case Methods Room). Our speaker is:

**Marcia I. Heron, Ph.D.**  
**Principal Research Scientist**  
**Pharmacia Corporation**

The title of Dr. Heron's talk is:

**"Matrix Metalloproteinase Inhibitors:  
A Novel Therapy for Heart Failure"**

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

## RECENT PUBLICATIONS FROM THE CVI

Loutzenhiser, R., Bidani, A., Chilton, L. Renal myogenic response - Kinetic attributes and physiological role. *Circ. Res.* 90(12):1316-1324, 2002.

Rothstein, E.C., Byron, K.L., Reed, R.E., Fliegel, L., Lucchesi, P.A. H<sub>2</sub>O<sub>2</sub>-induced Ca<sup>2+</sup> overload in NRVM involves ERK1/2 MAP kinases: role for an NHE-1-dependent pathway. *Am. J. Physiol. Heart Circ. Physiol.* 283(2):H598-H605, 2002.

Untch, B., Ahmad, S., Messmore, H.L., Schultz, C.L., Ma, Q., Hoppensteadt, D.A., Walenga, J.M., Fareed, J. Development of a non-human primate sub-clinical model

of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. *Thrombosis Res.* 106:149-156, 2002.

Iqbal, O., Ahmad, S., Lewis, B.E., Walenga, J.M., Rangel, Y., Fareed, J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. *Clin. Appl. Thrombosis/Hemostasis* 8(3):217-224, 2002.

## CHANGE IN PHS POLICY ON USE OF LAB ANIMALS

**NOTICE NUMBER: NOT-OD-02-064**

In the March 28, 2002, Federal Register (and the April 5, 2002, NIH Guide for Grants and Contracts), the NIH announced that it was considering a change in the PHS Policy on Humane Care and Use of Laboratory Animals to allow institutions to provide IACUC approval in a "just-in-time" fashion prior to award, as is now permitted for IRB approval. The comment period ended on May 28, 2002, and responses from the research community and institutional officials were overwhelmingly in favor of this change. Consequently, the NIH now announces that beginning with applications submitted for the October 1, 2002, receipt date (and any other receipt dates that result in applications being reviewed for May/June 2003 Councils), IACUC "just-in-time" will be in effect. That is, institutions will be permitted flexibility in the timing of IACUC review relative to submission of an application.

The NIH wants to emphasize certain principles and expectations of the "just-in-time" process for IACUC review and approval.

- The fundamental PHS Policy requirement that no award may be made without an approved Assurance and without verification of IACUC approval remains in effect. This change only affects the timing of the submission of the verification of that review.
- This change is intended to permit flexibility and discretion on the part of the institution. It is not a requirement that IACUC approval be deferred. Institutional officials retain the discretion to require IACUC approval prior to peer review in certain circumstances of their choosing if they so desire.
- Under no circumstances may an IACUC be pressured to approve a protocol, or be overruled on its decision to withhold approval. NIH peer review groups will continue to address the adequacy of animal usage and protections in their review of an application, and will continue to raise concerns about animal welfare issues. However, in no way is peer review intended to supersede or serve as a replacement for IACUC approval. An institution that elects

to use IACUC "just-in-time" bears the responsibility for supporting the role of the IACUC.

- It remains incumbent upon investigators to be totally forthcoming and timely in conveying to their IACUCs any modifications related to project scope and animal usage that may result from the NIH review and award process. Should an institution find that one of its investigators disregards his/her responsibilities, the institution may, for example, determine that all animal protocols from that investigator be subject to IACUC approval before it will permit submission of an application from that investigator.
- The existing PHS Policy requirement that modifications required by the IACUC be submitted to the NIH with the verification of IACUC approval remains in effect, and it remains the responsibility of institutions to communicate any IACUC-imposed changes to NIH staff.
- The NIH understands its responsibility to ensure that institutions are given adequate notice to allow for timely IACUC review prior to award, and will take appropriate internal measures to fulfill its responsibility to establish timely feedback. An announcement is published in the Federal Register (67 FR 51289), giving the precise language change and citation in the PHS Policy.

To see the Federal Register Notice in HTML format, go to:

[http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2002\\_register&docid=fr07au02-108](http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2002_register&docid=fr07au02-108).

To see the Federal Register Notice in PDF format, go to:

[http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2002\\_register&docid=fr07au02-108.pdf](http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2002_register&docid=fr07au02-108.pdf).

For questions or further information, contact:

Anthony Demsey, Ph.D.  
Senior Advisor for Policy  
Office of Extramural Research  
National Institutes of Health  
Building 1, Room 154  
Bethesda, MD 20892  
301/496-5127 (phone)  
301/496-3469 (fax)  
e-mail: [demsey@od.nih.gov](mailto:demsey@od.nih.gov)



## CARDIOLOGY- CVI RESEARCH DIVISION BASIC SCIENCE SEMINARS

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled:

Dr. Samarel.....September 27

The title of Dr. Samarel's talk is:

**"Molecular Biology of Cardiac Overload"**

Seminars are held at 12:30 pm in the Cardiology Conference Room, Rm 6291.

For further information, contact Dr. Samarel at x72821

## FIRST RANDALL LECTURE FEATURES MARBAN

The Walter C. Randall Distinguished Speaker Series sponsored by Abbot Laboratories and the Department of Physiology will host its first guest lecturer this fall. Dr. Eduardo Marban, Professor of the Institute of Molecular Cardiology at Johns Hopkins University, has been invited to speak on **Tuesday, October 1, 2002** at noon in Tobin Hall. His seminar presentation "**Gene Therapy for Cardiac Arrhythmias**" has been scheduled to coincide with Medicine Grand Rounds.



